Search results
Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second most common malignancy and the leading cause of cancer-related death globally. Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has been one of the greatest advances in recent years for the treatment of solid tumors including NSCLC.
20 sty 2021 · Relevance for patients: Immunotherapy has revolutionized the treatment of non-small cell lung cancer patients reaching better survival outcomes in first and second palliative setting and in...
9 lut 2022 · Here, we will summarize the current state of immunotherapy in lung cancer, discuss novel targets, and explore the intersection between DNA repair defects and immunotherapy.
13 maj 2021 · PDF. Practical Applications. •. Immunotherapy consists of a class of drugs that interact with the immune system to induce cancer cell apoptosis. Monoclonal antibodies against PD-1, PD-L1, and CTLA-4 are the most commonly used immune checkpoint inhibitors for patients with non–small cell lung cancer. •.
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Sun Min Lim 1, Min Hee Hong 2, Hye Ryun Kim 2,* Division of Hematology-Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
5 sty 2022 · The implementation of immunotherapies with checkpoint inhibitors has substantially improved therapeutic outcomes of patients with advanced or metastatic non–small-cell lung cancer (NSCLC).
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in combination with other ICIs or
